Answers are grounded in this paper and cite their sources.
Demonstrates that most LQT2 mutations cause Kv11.1 channel dysfunction via a correctable trafficking-deficient mechanism, highlighting a potential therapeutic strategy.
This is the first study to identify a dominant mechanism, class 2, for the loss of Kv11.1 channel function in LQT2 and to report that the class 2 phenotype for many of these mutant channels can be corrected. This suggests that if therapeutic strategies to correct protein trafficking abnormalities can be developed, it may offer clinical benefits for LQT2 patients.
No takes yet. Share an insight, caveat, or question.
Anderson et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: